QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Griffith Institute for Drug Discovery (GRIDD), Griffith University, Brisbane, QLD, Australia.
BMJ Open. 2022 Feb 25;12(2):e052032. doi: 10.1136/bmjopen-2021-052032.
Parkinson's disease (PD) is a neurodegenerative disorder associated with progressive disability. While the precise aetiology is unknown, there is evidence of significant genetic and environmental influences on individual risk. The Australian Parkinson's Genetics Study seeks to study genetic and patient-reported data from a large cohort of individuals with PD in Australia to understand the sociodemographic, genetic and environmental basis of PD susceptibility, symptoms and progression.
In the pilot phase reported here, 1819 participants were recruited through assisted mailouts facilitated by Services Australia based on having three or more prescriptions for anti-PD medications in their Pharmaceutical Benefits Scheme records. The average age at the time of the questionnaire was 64±6 years. We collected patient-reported information and sociodemographic variables via an online (93% of the cohort) or paper-based (7%) questionnaire. One thousand five hundred and thirty-two participants (84.2%) met all inclusion criteria, and 1499 provided a DNA sample via traditional post.
65% of participants were men, and 92% identified as being of European descent. A previous traumatic brain injury was reported by 16% of participants and was correlated with a younger age of symptom onset. At the time of the questionnaire, constipation (36% of participants), depression (34%), anxiety (17%), melanoma (16%) and diabetes (10%) were the most reported comorbid conditions.
We plan to recruit sex-matched and age-matched unaffected controls, genotype all participants and collect non-motor symptoms and cognitive function data. Future work will explore the role of genetic and environmental factors in the aetiology of PD susceptibility, onset, symptoms, and progression, including as part of international PD research consortia.
帕金森病(PD)是一种与进行性残疾相关的神经退行性疾病。虽然确切的病因尚不清楚,但有证据表明个体风险受到重大遗传和环境因素的影响。澳大利亚帕金森遗传学研究旨在研究澳大利亚一大群 PD 患者的遗传和患者报告数据,以了解 PD 易感性、症状和进展的社会人口统计学、遗传和环境基础。
在本报告的试点阶段,根据其药品福利计划记录中有三种或更多种抗 PD 药物的处方,通过澳大利亚服务机构协助邮寄,招募了 1819 名参与者。问卷调查时的平均年龄为 64±6 岁。我们通过在线(队列的 93%)或纸质(7%)问卷收集患者报告的信息和社会人口统计学变量。1532 名参与者(84.2%)符合所有纳入标准,1499 名参与者通过传统邮寄提供了 DNA 样本。
65%的参与者为男性,92%的参与者自认为是欧洲血统。16%的参与者报告曾有过创伤性脑损伤,且与发病年龄较小有关。在问卷调查时,36%的参与者报告有便秘,34%的参与者报告有抑郁,17%的参与者报告有焦虑,16%的参与者报告有黑色素瘤,10%的参与者报告有糖尿病。
我们计划招募性别匹配和年龄匹配的未受影响的对照组,对所有参与者进行基因分型,并收集非运动症状和认知功能数据。未来的工作将探索遗传和环境因素在 PD 易感性、发病、症状和进展中的作用,包括作为国际 PD 研究联盟的一部分。